Skip to content
OpenCapital
Get started

NAGE NAGE Pharmaceuticals segment — Operating Income (Loss)

Other segment segments

Consumer Products segment
$4.64M-15.8%
Ingredients segment
$4.54M-4.4%
Analytical Reference Standards and Services segment
$71K+14.5%

Similar metrics at other companies

Bausch + Lomb logo
BLCOPharmaceuticals — Operating Income (Loss)
$66M+500%
Baxter International logo
BAXPharmaceuticals — Segment operating income
$46M-27.0%
Vertex Pharmaceuticals logo
VRTXPharmaceuticals — income (loss)
$1.03B+59.6%
Thermo Fisher Scientific logo
TMOLaboratory Products and Biopharma Services — Operating Income (Loss)
$778M+6.4%
AMP
AMPHPharmaceutical Products — Net Income Loss
$6.42M-74.6%
Denali Therapeutics Inc. logo
DNLITherapeutics Segment — Operating Income (Loss)
-$137.36M+5.6%

Other financials

Income statement

See full
Revenue$31.5M+3.3%
Gross profit$20.0M+3.3%
Operating income$1.6M-67.0%
Net income$6.3M+24.8%
EPS (diluted)$0.07+16.7%

Balance sheet

See full
Cash & equivalents$66.5M+19.7%
Total debt$2.6M-26.9%
Total equity$82.3M+48.8%
Total assets$114.3M+40.6%

Cash flow

See full
Operating cash flow-$1.2M-115%

Valuation

See full
Market cap$254.07M-74.9%
Enterprise value$190.09M-79.7%
P/E13.6×-43.5×
P/S2×-6.8×

Profitability

See full
Gross margin64.3%+1.8pp
Operating margin10%-2.2pp
Net margin14.3%+1.2pp
FCF margin-70.4%—

Returns & leverage

See full
Return on equity27.1%-6.4pp
Debt / equity0×0.0×
Current ratio4.6×+0.9×

Where this comes from

Reported directly by NAGE in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: NAGE’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about NAGE's pharmaceuticals segment — operating income (loss).

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NAGE's pharmaceuticals segment — operating income (loss)?
NAGE (NAGE) reported pharmaceuticals segment — operating income (loss) of -$468K in Q1 2026.
How has NAGE's pharmaceuticals segment — operating income (loss) changed year-over-year?
NAGE's pharmaceuticals segment — operating income (loss) decreased by 27.2% year-over-year, from -$368K to -$468K.
What does pharmaceuticals segment — operating income (loss) mean?
Represents the profit or loss generated by the pharmaceutical segment after subtracting all operating expenses from gross profit. It is the definitive measure of the segment's operational performance and financial health. A positive value indicates a self-sustaining business, while a negative value highlights an investment-phase or underperforming segment.